|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.360 AUD | +5.83% |
|
-4.45% | -13.24% |
| 02-06 | ASX Biggest Losers | MT |
| 01-29 | Mesoblast to Start Site Enrollment in Pivotal Trial for Cell Therapy Label Extension; Shares Fall 4% | MT |
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 7.46M | 10.21M | 7.5M | 5.9M | 17.2M | |||||
Total Revenues | 7.46M | 10.21M | 7.5M | 5.9M | 17.2M | |||||
Cost of Goods Sold, Total | 85.73M | 63.57M | 54.92M | 41.07M | 39.94M | |||||
Gross Profit | -78.28M | -53.36M | -47.42M | -35.17M | -22.74M | |||||
Selling General & Admin Expenses, Total | 30.87M | 27.21M | 25.37M | 23.63M | 39.31M | |||||
R&D Expenses | - | - | - | - | - | |||||
Other Operating Expenses | -68K | 3K | -3.51M | -822K | 395K | |||||
Other Operating Expenses, Total | 30.8M | 27.21M | 21.87M | 22.8M | 39.7M | |||||
Operating Income | -109M | -80.57M | -69.29M | -57.97M | -62.44M | |||||
Interest Expense, Total | -15.94M | -16.91M | -19.44M | -20.66M | -21.75M | |||||
Interest And Investment Income | - | 3K | 831K | 1.82M | 3.55M | |||||
Net Interest Expenses | -15.94M | -16.9M | -18.61M | -18.83M | -18.2M | |||||
Currency Exchange Gains (Loss) | 1.47M | -536K | -163K | -76K | -106K | |||||
Other Non Operating Income (Expenses) | 5.22M | 5.51M | -2.88M | -1.57M | -6.18M | |||||
EBT, Excl. Unusual Items | -118M | -92.5M | -90.95M | -78.45M | -86.92M | |||||
Asset Writedown | - | - | 76K | - | - | |||||
In Process R&D Expenses | - | - | - | - | - | |||||
Other Unusual Items | 18.69M | 913K | 8.77M | -9.69M | -14.89M | |||||
EBT, Incl. Unusual Items | -99.63M | -91.59M | -82.1M | -88.15M | -102M | |||||
Income Tax Expense | -819K | -239K | -212K | -191K | 330K | |||||
Earnings From Continuing Operations | -98.81M | -91.35M | -81.89M | -87.96M | -102M | |||||
Net Income to Company | -98.81M | -91.35M | -81.89M | -87.96M | -102M | |||||
Net Income - (IS) | -98.81M | -91.35M | -81.89M | -87.96M | -102M | |||||
Net Income to Common Incl Extra Items | -98.81M | -91.35M | -81.89M | -87.96M | -102M | |||||
Net Income to Common Excl. Extra Items | -98.81M | -91.35M | -81.89M | -87.96M | -102M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.16 | -0.14 | -0.11 | -0.09 | -0.08 | |||||
Basic EPS - Continuing Operations | -0.16 | -0.14 | -0.11 | -0.09 | -0.08 | |||||
Basic Weighted Average Shares Outstanding | 605M | 649M | 739M | 987M | 1.21B | |||||
Net EPS - Diluted | -0.16 | -0.14 | -0.11 | -0.09 | -0.08 | |||||
Diluted EPS - Continuing Operations | -0.16 | -0.14 | -0.11 | -0.09 | -0.08 | |||||
Diluted Weighted Average Shares Outstanding | 605M | 649M | 739M | 987M | 1.21B | |||||
Normalized Basic EPS | -0.12 | -0.09 | -0.08 | -0.05 | -0.04 | |||||
Normalized Diluted EPS | -0.12 | -0.09 | -0.08 | -0.05 | -0.04 | |||||
American Depositary Receipts Ratio (ADR) | 10 | 10 | 10 | 10 | 10 | |||||
Supplemental Items | ||||||||||
EBITDA | -107M | -77.91M | -66.84M | -56.08M | -58.18M | |||||
EBITA | -108M | -79.06M | -67.8M | -56.49M | -58.48M | |||||
EBIT | -109M | -80.57M | -69.29M | -57.97M | -62.44M | |||||
EBITDAR | -103M | -74.71M | -65.74M | -55.78M | - | |||||
Total Revenues (As Reported) | - | 10.21M | - | - | 17.2M | |||||
Effective Tax Rate - (Ratio) | 0.82 | 0.26 | 0.26 | 0.22 | -0.32 | |||||
Total Deferred Taxes | -819K | -239K | -212K | -191K | 330K | |||||
Normalized Net Income | -73.95M | -57.81M | -56.84M | -49.03M | -54.33M | |||||
Interest on Long-Term Debt | 15.94M | 16.91M | 19.44M | 20.66M | 22.55M | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | 30.87M | 27.21M | 25.37M | 23.63M | - | |||||
Research And Development Expense From Footnotes | 53.01M | 32.82M | 27.19M | 25.35M | 34.81M | |||||
Net Rental Expense, Total | 3.6M | 3.2M | 1.1M | 300K | - | |||||
Imputed Operating Lease Interest Expense | 4.48M | 4.08M | 1.53M | 421K | - | |||||
Imputed Operating Lease Depreciation | -883K | -875K | -432K | -121K | - | |||||
Stock-Based Comp., COGS (Total) | 8.33M | 3.93M | 1.67M | 2.97M | 12.49M | |||||
Stock-Based Comp., R&D Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | 4.18M | 1.61M | 1.99M | 2.9M | - | |||||
Stock-Based Comp., SG&A Exp. (Total) | - | - | - | - | 9.6M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 12.51M | 5.54M | 3.66M | 5.87M | 22.09M |
- Stock Market
- Equities
- MSB Stock
- Financials Mesoblast Limited
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















